Sanofi forms pharma partnership with MyoKardia on a $200 million initiative to develop new therapies to help treat deadly genetic heart muscle disease.
The partnership will be an offshoot of Paris-based Sanofi's early-stage investment program, Sunrise, and will encompass three MyoKardia programs.
Two will be focused on hypertrophic cardiomyopathy (HCM) and the other is focused on dilated cardiomyopathy (DCM).
HCM is the leading cause of sudden cardiac death in young adults, and DCM the leading genetic illness requiring heart transplantation.
Funding will take the form of $200 million in equity investments, milestone payments and research and development services through 2018.
So far $45 million has already been received in an upfront licensing fee and an initial equity investment.
For further deal information visit Current Agreements (subscription required)
Report: Partnering Deals and Alliances with Sanofi
View: Partnering Scorecard in CP Insight– view top life science partnering deals by value
View: DealMetrics in CP Insight – the latest deal trend infographics for life science deal making
View: CP Insight’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
View: CP Insight’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity